question: Can Patient-derived organoids (PDOs) recapitulate patient responses in the clinic?
answer: Yes. Phenotypic and genotypic profiling of PDOs showed a high degree of similarity to the original patient tumors. Molecular profiling of tumor organoids was matched to drug-screening results, suggesting that PDOs could complement existing approaches in defining cancer vulnerabilities and improving treatment responses. In summary, PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.